Immunology & Autoimmune
Part of Biotech - Drug Development
 JNJ | Johnson & Johnson | $0.6t | $258.75 | +2.0% | 3.7M |
 ABBV | ABBVIE INC. | $464.4b | $272.38 | +1.8% | 3.9M |
 AMGN | Amgen Inc | $217.9b | $412.74 | +2.6% | 1.7M |
 BMY | Bristol-Myers Squibb Co. | $124.9b | $59.85 | +0.2% | 8.9M |
 REGN | Regeneron Pharmaceuticals Inc | $75.7b | $750.42 | +0.5% | 494.8K |
 ROIV | Roivant Sciences Ltd. Common Shares | $25.8b | $34.91 | -2.2% | 4.5M |
 IBRX | ImmunityBio, Inc. Common Stock | $10.9b | $9.76 | +0.8% | 10.6M |
 APGE | Apogee Therapeutics, Inc. Common Stock | $10.2b | $135.09 | 0.0% | N/A |
 PTGX | Protagonist Therapeutics, Inc | $9.1b | $140.97 | +1.7% | 761.1K |
 TGTX | TG Therapeutics, Inc. | $8.3b | $53.07 | +1.5% | 1.2M |
 SYRE | Spyre Therapeutics, Inc. Common Stock | $8.2b | $81.92 | +0.9% | 2.4M |
 IMVT | Immunovant, Inc. Common Stock | $6.9b | $32.04 | -0.2% | 940.4K |
 ORKA | Oruka Therapeutics, Inc. Common Stock | $5.6b | $79.58 | -0.8% | 695.9K |
 APLS | Apellis Pharmaceuticals, Inc. Common Stock | $5.2b | $41.04 | +0.0% | 68.6M |
 DNTH | Dianthus Therapeutics, Inc. Common Stock | $4.9b | $84.92 | -0.6% | 366.9K |
 ARQT | Arcutis Biotherapeutics, Inc. Common Stock | $3.2b | $24.26 | +1.0% | 1.4M |
 RCUS | Arcus Biosciences, Inc. | $3.1b | $24.53 | +1.0% | 828.3K |
 CLDX | Celldex Therapeutics, Inc | $2.5b | $30.72 | -1.8% | 1.4M |
 VERA | Vera Therapeutics, Inc. Class A Common Stock | $2.2b | $29.79 | +2.9% | 2.6M |
 ADMA | ADMA Biologics, Inc. | $2.2b | $10.22 | -0.3% | 2.1M |
 AUPH | Aurinia Pharmaceuticals Inc | $2.1b | $15.98 | +2.2% | 538.0K |
 BHVN | Biohaven Ltd. | $1.9b | $11.89 | -1.7% | 1.9M |
 XNCR | Xencor, Inc. | $1.8b | $24.39 | -0.4% | 683.7K |
 ZBIO | Zenas BioPharma, Inc. Common Stock | $1.8b | $27.98 | +4.6% | 271.8K |
 SEPN | Septerna, Inc. Common Stock | $1.8b | $36.63 | +1.0% | 540.1K |
 FBRX | Forte Biosciences, Inc. Common Stock | $1.6b | $76.98 | 0.0% | N/A |
 ANAB | AnaptysBio, Inc. Common Stock | $1.5b | $45.71 | -4.7% | 566.1K |
 NKTR | Nektar Therapeutics | $1.5b | $40.18 | +0.8% | 1.3M |
 CGEM | Cullinan Therapeutics, Inc. Common Stock | $1.0b | $15.93 | -3.9% | 681.0K |
 MLTX | MoonLake Immunotherapeutics Class A Ordinary Shares | $1.0b | $10.90 | -1.6% | 1.1M |
 CRVS | Corvus Pharmaceuticals, Inc. | $0.9b | $10.41 | -1.3% | 1.0M |
 JBIO | Jade Biosciences, Inc. Common Stock | $0.9b | $13.79 | +2.8% | 788.6K |
 ALMS | Alumis Inc. Common Stock | $0.9b | $6.79 | -2.2% | 1.4M |
 RIGL | Rigel Pharmaceuticals Inc. (New) | $0.9b | $47.16 | +4.2% | 186.2K |
 AVTX | Avalo Therapeutics, Inc. Common Stock | $0.8b | $13.57 | -0.1% | 438.2K |
 IMMX | Immix Biopharma, Inc. Common Stock | $0.8b | $9.49 | -1.7% | 863.6K |
 ANNX | Annexon, Inc. Common Stock | $0.8b | $4.00 | -0.1% | 2.1M |
 STTK | Shattuck Labs, Inc. Common Stock | $0.7b | $5.66 | -3.4% | 1.0M |
 ACRS | Aclaris Therapeutics, Inc. | $0.6b | $3.42 | -8.5% | 8.5M |
 CLYM | Climb Bio, Inc. Common Stock | $0.6b | $10.72 | +0.4% | 658.6K |
 ZURA | Zura Bio Limited Class A Ordinary Shares | $414.9m | $4.17 | +5.6% | 1.9M |
 KYTX | Kyverna Therapeutics, Inc. Common Stock | $384.7m | $6.28 | +0.2% | 582.2K |
 ENTA | Enanta Pharmaceuticals, Inc | $377.5m | $12.39 | +1.8% | 149.4K |
 CABA | Cabaletta Bio, Inc. Common Stock | $339.1m | $2.04 | -2.0% | 2.0M |
 FATE | Fate Therapeutics, Inc. | $278.0m | $2.16 | -5.9% | 779.4K |
 IPSC | Century Therapeutics, Inc. Common Stock | $277.0m | $1.38 | -3.4% | 653.2K |
 UPB | Upstream Bio, Inc. Common Stock | $276.0m | $4.61 | +0.4% | 822.8K |
 SABS | SAB Biotherapeutics, Inc. Common Stock | $271.1m | $2.84 | -1.7% | 647.2K |
 IFRX | InflaRx N.V. Common Stock | $253.5m | $1.56 | -1.6% | 449.2K |
 EVMN | Evommune, Inc. | $251.1m | $6.37 | -5.9% | 2.0M |